Lakefront Biotherapeutics (GLPGF) EBIT (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported EBIT for 13 consecutive years, with -$50.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 21.63% year-over-year to -$50.6 million in Q2 2026; TTM through Jun 2026 was $468.1 million, a 227.14% increase from a year earlier, with the FY2025 full-year figure at $333.3 million, up 263.53% from the prior year.
• EBIT was -$50.6 million for Q2 2026 at Lakefront Biotherapeutics, up from -$74.6 million in the prior quarter.
• Over five years, EBIT peaked at $881.4 million in Q4 2025 and troughed at -$288.1 million in Q3 2025.
• A 5-year average of $12.4 million and a median of -$29.9 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 5629.05% in 2023 and tumbled 1276.11% in 2024, its largest moves.
• Over 5 years, EBIT stood at $4.1 million in 2022, then soared by 5629.05% to $233.8 million in 2023, then slumped by 67.41% to $76.2 million in 2024, then soared by 1056.85% to $881.4 million in 2025, then slumped by 105.74% to -$50.6 million in 2026.
• The last three EBIT figures came in at -$50.6 million (Q2 2026), -$74.6 million (Q1 2026), and $881.4 million (Q4 2025), per Business Quant data.